Patents Assigned to Primus Pharmceuticals, Inc.
  • Reduced dose metaxalone formulations
    Patent number: 11918559
    Abstract: Oral dosage forms of metaxalone having improved bioavailability in the fed and fasted states, including dosage forms that employ a reduced dose based on such improved bioavailability.
    Type: Grant
    Filed: May 14, 2023
    Date of Patent: March 5, 2024
    Assignee: Primus Pharmceuticals, Inc.
    Inventors: Mukteeshwar Gande, Robert M. Levy